LDN-212854

LDN-212854 is a potent and selective small molecule inhibitor of bone morphogenetic protein (BMP) type I receptor kinases, specifically exhibiting a strong preference for inhibiting activin receptor-like kinase 2 (ALK2, also known as ACVR1) with high selectivity over other BMP type I receptors (ALK1, ALK3) and minimal inhibition of TGF-β pathway type I receptors (ALK4, ALK5). It binds as a type I ATP-competitive inhibitor targeting the kinase hinge region and is notable for its ability to inhibit ALK2-mediated signaling at nanomolar concentrations. LDN-212854 has been primarily used as a chemical probe in research to dissect ALK2 signaling and in disease models of fibrodysplasia ossificans progressiva (FOP) and heterotopic ossification, where it prevents abnormal bone formation. It was developed as an improvement over less selective BMP inhibitors, offering a valuable tool for understanding BMP signaling and the therapeutic potential of selective ALK2 inhibition[1][2][6][7][8].